Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment

• DOI: 10.5604/01.3001.0010.7536
• Publication Date: 2017-12-27T23:53:49Z
• Authors: Stefano Gitto; Arrigo F.G. Cicero; Elisabetta Loggi; Marina Giovannini; Fabio Conti; Elena Grandini; Valeria Guarneri; Alessandra Scuteri; Giovanni Vitale; Carmela Cursaro; Claudio Borghi; Pietro Andreone
• Keywords: Lipid Profile

Introduction. Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose patients with chronic after therapy direct acting antivirals (DAA). Material methods. We considered consecutively treated between January November 2015 recording clinical data at baseline week 24 follow-up. Frozen serum samples were used for apolipoprotein A1 (apoA1), B (apoB) lipoprotein (a) [Lp(a)]. Wilcoxon test utilized estimate trends Logistic Regression predictors changes. Results. enrolled 100 patients, mostly cirrhotic (81%) genotype 1b (59%). Ninety-three achieved sustained virological response (SVR), while 7 relapsed. Homeostasis model assessment insulin resistance declined (from 3 2.7, p < 0.001); non-high density (HDL) cholesterol increased from 102 ± 29 116 35 (p 0.001), Lp(a) 5.6 6.5 9.8 11.5 mg/dL 0.001). Rise low-density lipoprotein/HDL apoB/apoA1 ratio registered 1.79 1.10 2.08 1.05 0.48 0.18 0.53 mg/dL, conducted a subanalysis on relapse. In this subgroup, no change profile recorded. At multivariate analysis emerged that the addition ribavirin DAA, represented an independent predictor (OR 3.982, 95% CI 1.206-13.144, = 0.023). Conclusion. DAA led reduction resistance. contrast, pro-atherogenic observed SVR. Further studies will be necessary cardiovascular balance amelioration negative profile.